F8 and hemophilia A: This study aims to evaluate the clinical outcomes and management strategies of hemophilia A and B patients receiving individualized glycopegylated EHL factor prophylaxis of FVIII/FIX therapy at a tertiary care center, addressing critical questions regarding effectiveness, safety, and patient QoL.